Illumina Inc. (ILMN) continues to make strategic moves to strengthen and expand its position in the bio-tech sector. The company recently reported Q2 earnings, surpassing Wall Street's estimates, and is expected to release further earnings on Tuesday. Chief Commercial Officer
Everett Cunningham was recently appointed, and Fluent BioSciences was acquired to accelerate
single-cell analysis and discovery to a broader customer base. The final resolution for Illumina's Grail saga was also set, with the board of directors approving the spin-off of
GRAIL and the subsequent divestiture of GRAIL. The Illumina stock has seen increased interest from investment firms such as
Atria Investments Inc., Swedbank AB, and O Shaughnessy Asset Management LLC, each purchasing significant shares of the company. Illumina continues to innovate in its offerings, launching
DRAGEN v4.3 for comprehensive and accurate genomic industry-leading innovations, and driving genomic testing as a standard in oncology with collaborative research presented at ASCO.
Illumina ILMN News Analytics from Fri, 10 Nov 2023 08:00:00 GMT to Sat, 03 Aug 2024 15:27:44 GMT -
Rating 8
- Innovation 7
- Information 8
- Rumor -3
